Drug intelligence / Profile preview

Xianshen Decoction formula granule

Development stage: Unknown
Lead developer: First Affiliated Hospital of Guangzhou University of Chinese Medicine
Administration: Oral

Overview

Xianshen Decoction formula granule is a traditional Chinese medicine (TCM) formulation developed by the Oncology Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine. It is currently being investigated in a Phase 3 clinical trial for its efficacy in preventing and treating radiation-induced oral mucositis in patients with nasopharyngeal carcinoma when combined with radiotherapy and chemotherapy. As a formula granule, it is likely administered orally.

Other names: Xiansen Decoction仙参汤颗粒剂

Beyond the preview

Go deeper on Xianshen Decoction formula granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xianshen Decoction formula granule.

Explore the full profile